Sangamo, TxCell announce completion of acquisition of TxCell ordinary shares

Sangamo Therapeutics and TxCell jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of EURO$2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell, as per the terms of the Share Purchase Agreement entered into on July 20, 2018 and announced previously by TxCell and Sangamo in a joint press release dated July 23, 2018. TxCell will now operate as a subsidiary of Sangamo. Sangamo expects to file on October 2, 2018 a cash simplified tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of EURO$2.58 per share. Subject to obtaining at least 95% of the share capital and voting rights of TxCell upon completion of the simplified tender offer, Sangamo will launch a squeeze-out procedure. Following the completion of the squeeze-out procedure, Sangamo will delist TxCell. TxCell’s operations will remain based in Valbonne, France.
https://thefly.com/landingPageNews.php?id=2797685